Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: A randomized controlled trial

Shankar P. Nagaraju, Adam Cohn, Ayub Akbari, Janet L. Davis, Deborah L. Zimmerman

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Anemia secondary to iron deficiency is common in patients with non-dialysis dependent chronic kidney disease (ND-CKD) but it is unclear if oral supplementation is as effective as intravenous (IV) supplementation in re-establishing iron stores. The purpose of this study was to determine if oral Heme Iron Polypeptide (HIP) is as effective as IV iron sucrose in the treatment of iron-deficiency anemia for patients with ND-CKD. Methods. Forty ND-CKD patients were randomized; 18 to HIP 11 mg orally 3 times per day and 22 to IV iron sucrose 200 mg monthly for 6 months. Baseline clinical and laboratory data were collected for all patients. The primary and secondary outcomes for the study were hemoglobin (Hgb) concentration and iron indices [ferritin and percentage transferrin saturation (TSAT)] at the end of 6 months respectively. Adverse events were also compared. Results: The baseline demographic characteristics and laboratory values were similar for the two groups. After 6 months of treatment, Hb in the HIP group was 117 g/L and 113 g/L in the IV sucrose group (p = 0.37). The TSAT at 6 months was not different between the two groups {p = 0.82}but the serum ferritin was significantly higher in the IV iron sucrose group {85.5 ug/L in HIP and 244 ug/L; p = 0.004}. Overall adverse events were not different between the groups. Conclusion: HIP is similar in efficacy to IV iron sucrose in maintaining hemoglobin in ND-CKD patients with no differences in adverse events over 6 months. It is unclear if the greater ferritin values in the IV iron sucrose group are clinically significant. Trial registration. ClinicalTrials.gov: NCT00318812.

Original languageEnglish
Article number64
JournalBMC Nephrology
Volume14
Issue number1
DOIs
Publication statusPublished - 22-03-2013

Fingerprint

saccharated ferric oxide
Iron-Deficiency Anemias
Heme
Chronic Renal Insufficiency
Iron
Randomized Controlled Trials
Peptides
Ferritins
Therapeutics
Transferrin
Hemoglobins
Sucrose
Anemia
Demography
Outcome Assessment (Health Care)

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

@article{6b770746603340a287a183aa4a75df5b,
title = "Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: A randomized controlled trial",
abstract = "Background: Anemia secondary to iron deficiency is common in patients with non-dialysis dependent chronic kidney disease (ND-CKD) but it is unclear if oral supplementation is as effective as intravenous (IV) supplementation in re-establishing iron stores. The purpose of this study was to determine if oral Heme Iron Polypeptide (HIP) is as effective as IV iron sucrose in the treatment of iron-deficiency anemia for patients with ND-CKD. Methods. Forty ND-CKD patients were randomized; 18 to HIP 11 mg orally 3 times per day and 22 to IV iron sucrose 200 mg monthly for 6 months. Baseline clinical and laboratory data were collected for all patients. The primary and secondary outcomes for the study were hemoglobin (Hgb) concentration and iron indices [ferritin and percentage transferrin saturation (TSAT)] at the end of 6 months respectively. Adverse events were also compared. Results: The baseline demographic characteristics and laboratory values were similar for the two groups. After 6 months of treatment, Hb in the HIP group was 117 g/L and 113 g/L in the IV sucrose group (p = 0.37). The TSAT at 6 months was not different between the two groups {p = 0.82}but the serum ferritin was significantly higher in the IV iron sucrose group {85.5 ug/L in HIP and 244 ug/L; p = 0.004}. Overall adverse events were not different between the groups. Conclusion: HIP is similar in efficacy to IV iron sucrose in maintaining hemoglobin in ND-CKD patients with no differences in adverse events over 6 months. It is unclear if the greater ferritin values in the IV iron sucrose group are clinically significant. Trial registration. ClinicalTrials.gov: NCT00318812.",
author = "Nagaraju, {Shankar P.} and Adam Cohn and Ayub Akbari and Davis, {Janet L.} and Zimmerman, {Deborah L.}",
year = "2013",
month = "3",
day = "22",
doi = "10.1186/1471-2369-14-64",
language = "English",
volume = "14",
journal = "BMC Nephrology",
issn = "1471-2369",
publisher = "BioMed Central",
number = "1",

}

Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients : A randomized controlled trial. / Nagaraju, Shankar P.; Cohn, Adam; Akbari, Ayub; Davis, Janet L.; Zimmerman, Deborah L.

In: BMC Nephrology, Vol. 14, No. 1, 64, 22.03.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients

T2 - A randomized controlled trial

AU - Nagaraju, Shankar P.

AU - Cohn, Adam

AU - Akbari, Ayub

AU - Davis, Janet L.

AU - Zimmerman, Deborah L.

PY - 2013/3/22

Y1 - 2013/3/22

N2 - Background: Anemia secondary to iron deficiency is common in patients with non-dialysis dependent chronic kidney disease (ND-CKD) but it is unclear if oral supplementation is as effective as intravenous (IV) supplementation in re-establishing iron stores. The purpose of this study was to determine if oral Heme Iron Polypeptide (HIP) is as effective as IV iron sucrose in the treatment of iron-deficiency anemia for patients with ND-CKD. Methods. Forty ND-CKD patients were randomized; 18 to HIP 11 mg orally 3 times per day and 22 to IV iron sucrose 200 mg monthly for 6 months. Baseline clinical and laboratory data were collected for all patients. The primary and secondary outcomes for the study were hemoglobin (Hgb) concentration and iron indices [ferritin and percentage transferrin saturation (TSAT)] at the end of 6 months respectively. Adverse events were also compared. Results: The baseline demographic characteristics and laboratory values were similar for the two groups. After 6 months of treatment, Hb in the HIP group was 117 g/L and 113 g/L in the IV sucrose group (p = 0.37). The TSAT at 6 months was not different between the two groups {p = 0.82}but the serum ferritin was significantly higher in the IV iron sucrose group {85.5 ug/L in HIP and 244 ug/L; p = 0.004}. Overall adverse events were not different between the groups. Conclusion: HIP is similar in efficacy to IV iron sucrose in maintaining hemoglobin in ND-CKD patients with no differences in adverse events over 6 months. It is unclear if the greater ferritin values in the IV iron sucrose group are clinically significant. Trial registration. ClinicalTrials.gov: NCT00318812.

AB - Background: Anemia secondary to iron deficiency is common in patients with non-dialysis dependent chronic kidney disease (ND-CKD) but it is unclear if oral supplementation is as effective as intravenous (IV) supplementation in re-establishing iron stores. The purpose of this study was to determine if oral Heme Iron Polypeptide (HIP) is as effective as IV iron sucrose in the treatment of iron-deficiency anemia for patients with ND-CKD. Methods. Forty ND-CKD patients were randomized; 18 to HIP 11 mg orally 3 times per day and 22 to IV iron sucrose 200 mg monthly for 6 months. Baseline clinical and laboratory data were collected for all patients. The primary and secondary outcomes for the study were hemoglobin (Hgb) concentration and iron indices [ferritin and percentage transferrin saturation (TSAT)] at the end of 6 months respectively. Adverse events were also compared. Results: The baseline demographic characteristics and laboratory values were similar for the two groups. After 6 months of treatment, Hb in the HIP group was 117 g/L and 113 g/L in the IV sucrose group (p = 0.37). The TSAT at 6 months was not different between the two groups {p = 0.82}but the serum ferritin was significantly higher in the IV iron sucrose group {85.5 ug/L in HIP and 244 ug/L; p = 0.004}. Overall adverse events were not different between the groups. Conclusion: HIP is similar in efficacy to IV iron sucrose in maintaining hemoglobin in ND-CKD patients with no differences in adverse events over 6 months. It is unclear if the greater ferritin values in the IV iron sucrose group are clinically significant. Trial registration. ClinicalTrials.gov: NCT00318812.

UR - http://www.scopus.com/inward/record.url?scp=84875075938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875075938&partnerID=8YFLogxK

U2 - 10.1186/1471-2369-14-64

DO - 10.1186/1471-2369-14-64

M3 - Article

C2 - 23514036

AN - SCOPUS:84875075938

VL - 14

JO - BMC Nephrology

JF - BMC Nephrology

SN - 1471-2369

IS - 1

M1 - 64

ER -